Last $21.15 USD
Change Today +0.025 / 0.12%
Volume 5.4K
TKPYY On Other Exchanges
Symbol
Exchange
Tokyo
OTC US
OTC US
Frankfurt
As of 10:16 AM 11/26/14 All times are local (Market data is delayed by at least 15 minutes).

Financial Statements for takeda pharmaceutic-sp adr (TKPYY)

Year over year, Takeda Pharmaceutical Company Limited has seen their bottom line shrink from ¥131.2B JPY to ¥106.7B JPY despite an increase in revenues from ¥1.6T JPY to ¥1.7T JPY. An increase in the percentage of sales devoted to income tax expenses from -0.25% to 2.91% was a key component in the falling bottom line in the face of rising revenues.
View Income Statement In U.S. Dollar
Currency in
Millions of Japanese Yens
As of:Mar 31
2011
Restated
JPY
Mar 31
2012
JPY
Mar 31
2013
JPY
Mar 31
2014
JPY
4 Year
Trend
Revenues1,419,385.01,508,932.01,557,267.01,691,685.0
TOTAL REVENUES1,419,385.01,508,932.01,557,267.01,691,685.0
Cost of Goods Sold317,582.0433,194.0447,628.0490,263.0
GROSS PROFIT1,101,803.01,075,738.01,109,639.01,201,422.0
Selling General & Admin Expenses, Total734,719.0810,711.0987,134.0577,387.0
R&D Expenses------341,560.0
Depreciation & Amortization, Total------143,202.0
OTHER OPERATING EXPENSES, TOTAL734,719.0810,711.0987,134.01,062,149.0
OPERATING INCOME367,084.0265,027.0122,505.0139,273.0
Interest Expense-1,335.0-1,883.0-3,323.0-30,720.0
Interest and Investment Income6,191.06,296.05,192.049,297.0
NET INTEREST EXPENSE4,856.04,413.01,869.018,577.0
Income (Loss) on Equity Investments451.0302.0866.01,000.0
Currency Exchange Gains (Loss)---2,382.0613.0-11,750.0
Other Non-Operating Income (Expenses)-819.03,245.0-12,685.0-32,011.0
EBT, EXCLUDING UNUSUAL ITEMS371,572.0270,605.0113,168.0115,089.0
Gain (Loss) on Sale of Investments----53,071.039,658.0
Gain (Loss) on Sale of Assets--17,596.04,026.0--
Other Unusual Items, Total---35,723.0-40,558.04,103.0
Other Unusual Items---35,489.03,090.0--
EBT, INCLUDING UNUSUAL ITEMS371,572.0252,478.0129,707.0158,850.0
Income Tax Expense121,325.0125,207.0-3,880.049,292.0
Minority Interest in Earnings-2,379.0-3,109.0-2,343.0-2,900.0
Earnings from Continuing Operations250,247.0127,271.0133,587.0109,558.0
NET INCOME247,868.0124,162.0131,244.0106,658.0
NET INCOME TO COMMON INCLUDING EXTRA ITEMS247,868.0124,162.0131,244.0106,658.0
NET INCOME TO COMMON EXCLUDING EXTRA ITEMS247,868.0124,162.0131,244.0106,658.0
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TKPYY:US $21.15 USD +0.025

TKPYY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $44.11 USD -0.0535
Astellas Pharma Inc ¥1,709 JPY -13.50
Baxter International Inc $72.40 USD -0.04
Becton Dickinson and Co $138.67 USD +3.94
Shire PLC 4,510 GBp +42.00
View Industry Companies
 

Industry Analysis

TKPYY

Industry Average

Valuation TKPYY Industry Range
Price/Earnings 35.4x
Price/Sales 2.1x
Price/Book 1.5x
Price/Cash Flow 11.8x
TEV/Sales 1.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TAKEDA PHARMACEUTIC-SP ADR, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.